Concord Drugs Limited is an Indian pharmaceutical company incorporated in **1995**, specializing in the manufacture of licensed drugs and advanced drug delivery systems. The company operates a **WHO-GMP certified** and **cGMP-compliant** contract manufacturing Formulation-Fill-Finish facility, providing end-to-end solutions from pharmaceutical development to finished products. --- ### **Core Technical Capabilities & Specialized Product Portfolio** The company focuses on high-growth segments including **Ready-to-Fill Pellets** and **Finished Pharmaceutical Formulations**. Its technical expertise is centered on complex delivery mechanisms designed to improve patient outcomes and drug efficacy. * **Advanced Drug Delivery Systems (ADDS):** Expertise in **MUPS (Multiple Unit Pellet System)**, Sustained Release (**SR**), and Modified Release pellets. * **Formulation Technologies:** Specialized processing for Enteric Coating (**EC**), Delayed Release (**DR**), Immediate Release (**IR**), and Sustained Release (**SR**) applications. * **Service Spectrum:** Comprehensive manufacturing and trading of chemical and pharmaceutical materials, including tablets, capsules, and injectables. * **Therapeutic Focus:** * **Oncology & Immunology:** Primary growth drivers due to expanding patient populations. * **Endocrinology:** Driven by the rapid adoption of **GLP-1 agonist medications** for diabetes and obesity. * **Neurology & Mental Health:** Focus on next-generation biotherapeutics. * **Antibacterials:** Continued supply of essential anti-infectives. --- ### **Operational Infrastructure & Strategic R&D** Operations are centralized in **Telangana**, supported by an administrative hub in Hyderabad. The company’s R&D efforts are dedicated to new product creation, quality enhancement, and cost affordability. * **Manufacturing Plant:** Survey No. **249**, Brahmanapally Village, Hayatnagar Mandal, R.R. District - **501511**. * **Administrative Office:** L B Nagar, Hyderabad - **500074**. * **Regulatory Alignment:** The company is currently prioritizing the **Ministry of Health and Family Welfare’s** revised **Schedule M** norms. It aims for full compliance ahead of the **December 31, 2025** deadline to qualify for global certifications such as **WHO-GMP** and **PIC/S**. --- ### **Corporate Structure & Equity Distribution** As of **March 31, 2025**, the company maintains a consolidated financial structure following the acquisition of a subsidiary. It is listed on the **BSE** (ISIN: **INE858L01010**). * **Subsidiary:** **Proton Remedies Private Limited** (100% acquisition completed **March 31, 2023**, for **₹1.415 Crore**). * **Share Capital Distribution (as of March 31, 2025):** | Particulars | No. of Shares | % Share Capital | | :--- | :--- | :--- | | **CDSL** | **7,670,373** | **76.70%** | | **NSDL** | **1,738,227** | **17.38%** | | **Physical** | **591,400** | **5.91%** | | **Total** | **10,000,000** | **100.00%** | --- ### **Capital Infusion & Modernization Strategy** In **July 2025**, the company initiated a strategic fund-raising exercise to modernize infrastructure and strengthen liquidity. This involves increasing the **Authorized Capital** from **₹11.00 Crore** to **₹15.50 Crore**. **Fund Raising Details:** * **Preferential Equity Allotment:** Up to **31,75,000** shares at **₹36.30** per share, aggregating to **₹11.53 Crore**. * **Convertible Warrants:** Up to **20,25,000** warrants at **₹36.30** each, aggregating to **₹7.35 Crore**. * **25%** (approx. **₹1.84 Crore**) payable at subscription. * **75%** (approx. **₹5.51 Crore**) payable upon exercise within **18 months**. **Planned Utilization of Funds (12-15 Month Horizon):** | Purpose | Allocation (Approx.) | Key Activities | | :--- | :--- | :--- | | **Manufacturing Upgradation** | **₹4.32 Crore** (37.5%) | Compliance with **Revised Schedule M - cGMP 2022**; HVAC systems; automation (QMS, LIMS). | | **Working Capital** | **₹4.32 Crore** (37.5%) | Procurement of **APIs** and raw materials; supply chain and marketing. | | **General Corporate** | Remaining Balance | Strengthening the balance sheet and meeting recurring overheads. | --- ### **Financial Performance Summary** The company maintains a stable revenue base, though profitability has faced pressure from rising operational expenses and taxation. | Metric (Consolidated) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue** | **₹45.26 crore** | **₹44.93 crore** | | **Net Profit** | **₹33.62 lakhs** | **₹47.24 lakhs** | | Metric (Standalone) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue** | **₹36.95 crore** | **₹43.27 crore** | | **Net Profit** | **₹29.57 lakhs** | **₹41.94 lakhs** | --- ### **Critical Risk Factors & Regulatory Challenges** Investors should note significant risks related to historical financial practices, regulatory non-compliance, and internal control deficiencies. **1. Regulatory & Legal Findings:** * **SEBI Adjudication (August 2023):** Established that the company engaged in **fraudulent practices** and **sham transactions** between **FY 2015-16 and FY 2019-20**. Findings included **fake invoices** and transactions with no actual movement of goods. * **MCA Non-Compliance:** Notices received for delays in filing **Cost Audit Reports** for **FY 2023-24**; compounding proceedings have been initiated. * **Labour Codes:** Incremental liabilities estimated following the **November 21, 2025**, implementation of **New Labour Codes**. **2. Financial & Audit Discrepancies:** * **Unprovisioned Receivables:** Auditors highlighted **₹4.14 Crores** (as of May 2025) outstanding for over **2 years** without provision for bad debts. * **Related Party Transactions (RPT):** SEBI investigations revealed non-disclosure of related parties (e.g., **Proton, Neutron, Cortex, Austrazen**) and lack of required approvals. * **Struck-off Entities:** Continued reporting of receivables from **Safal Agri BioTech Private Limited**, an entity struck off since **FY 2012-13**. * **Internal Controls:** Forensic audits identified a lack of **Internal Financial Controls (IFC)**, including missing delivery challans and e-way bills. **3. Historical Transaction Discrepancies (Cortex Laboratories):** | Year | Sales (₹ Lakhs) | Purchase of Raw Material (₹ Lakhs) | Balance from CLPL (₹ Lakhs) | | :--- | :--- | :--- | :--- | | **2017-18** | - | **1,906.77** | **1,879.94** | | **2018-19** | **902.46** | **1,318.65** | **2,269.59** | | **2019-20** | **256.90** | **361.87** | **89.09** | **4. Employee Benefits & Statutory Dues:** * The company is **not regular** in depositing **Provident Fund** contributions. * Lack of **independent actuarial valuations** for **Gratuity** and no provision for **Leave Encashment**.